GLP-1 for weight loss: what 3 months actually looks like

What did @cscandleco actually say?

Honestly, this one is tricky to fact-check. The transcript captured by the platform appears to be song lyrics or audio noise, not the creator's actual spoken words. What we do have is the caption, which tells us @cscandleco started GLP-1 medications about three months ago, combined them with diet and exercise, and framed the decision as a response to weight gain that had become a health concern. They describe doing extensive research beforehand and feeling positive about the results so far.

Because the transcript is unreadable, this fact-check focuses on the specific claims embedded in the caption, which are: that GLP-1s are an appropriate tool for weight-related health concerns, that combining them with diet and exercise is the right approach, and that three months is a meaningful timeframe for evaluating results.

Does the science back this up?

On the core points, yes, the science broadly supports the framework @cscandleco describes. GLP-1 receptor agonists have robust trial data behind them, and the combination with lifestyle changes is not just recommended, it is how the pivotal trials were actually designed.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) tested semaglutide 2.4mg alongside a reduced-calorie diet and increased physical activity. Participants lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide produced even larger reductions, up to 22.5% at the highest dose, again combined with lifestyle intervention. Neither drug was tested in isolation from behavioral changes, which matters for how we interpret real-world results.

Three months is a real but early checkpoint. Most participants in these trials saw meaningful weight loss by week 12, but the trajectory typically continues well beyond that window.

What did they get wrong (or right)?

Credit where it is due: framing GLP-1 use alongside diet and exercise is exactly right, not a disclaimer or a hedge. The clinical data consistently shows that people who maintain lifestyle changes alongside medication lose more weight and experience better metabolic outcomes than those who rely on the drug alone.

The part that deserves scrutiny is the phrase that all research found was "wonderful." That framing glosses over real side effect data. Nausea affects roughly 44% of semaglutide users in trials (Wilding et al., 2021). Gastrointestinal events are the leading reason people discontinue. There is also ongoing research into muscle mass loss during rapid weight reduction with GLP-1 agents, with some researchers suggesting resistance training may help preserve lean mass (Bikou et al., 2024, Nutrients). The creator does mention weightlifting in their hashtags, which is a genuinely smart pairing, but "wonderful" research does not cover the full picture.

No misleading medical claims were made. No doses were recommended. This is a personal experience share, not medical advice, and it reads that way.

What should you actually know?

GLP-1 receptor agonists are among the most studied weight management tools available right now, but they are not without tradeoffs. Here is what the evidence actually shows beyond the headline numbers.

• Weight regain after stopping is well-documented. The STEP 4 trial (Rubino et al., 2021, JAMA) found participants regained two-thirds of lost weight within a year of discontinuing semaglutide. This is not a failure of willpower; it reflects how these drugs work on appetite signaling.
• The combination with resistance training, which @cscandleco appears to be doing based on the weightlifting hashtag, is worth taking seriously. Preserving muscle during a caloric deficit matters for long-term metabolic health.
• Compounded versions of semaglutide and tirzepatide are not equivalent to FDA-approved brand-name products. Formulation, purity, and dosing accuracy differ. If you are using a compounded product, that is a different clinical situation than the trial data describes.
• GLP-1s do not cure obesity or type 2 diabetes. They are tools that require ongoing use and clinical supervision to maintain effect.

Bottom line

@cscandleco is not making outlandish claims. The framework they describe, starting GLP-1 therapy for weight-related health concerns and combining it with diet and exercise at a three-month mark, is consistent with how these drugs are intended to be used. The research enthusiasm is understandable but slightly oversold. A more complete picture includes the side effect profile, the weight regain data after discontinuation, and the importance of medical supervision throughout. This video is a personal journey share, not a clinical recommendation, and it should be read as exactly that.